JP7665339B2 - 既存の相互作用を最小化する改変結合分子 - Google Patents

既存の相互作用を最小化する改変結合分子 Download PDF

Info

Publication number
JP7665339B2
JP7665339B2 JP2020572773A JP2020572773A JP7665339B2 JP 7665339 B2 JP7665339 B2 JP 7665339B2 JP 2020572773 A JP2020572773 A JP 2020572773A JP 2020572773 A JP2020572773 A JP 2020572773A JP 7665339 B2 JP7665339 B2 JP 7665339B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020572773A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531245A (ja
JP2021531245A5 (cg-RX-API-DMAC10.html
Inventor
サムナー ジアンヌ
チェン チーホア
パートリッジ マイケル
トッリ アルバート
ラジャドヒャクシャ マノジュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2021531245A publication Critical patent/JP2021531245A/ja
Publication of JP2021531245A5 publication Critical patent/JP2021531245A5/ja
Priority to JP2025064335A priority Critical patent/JP2025100662A/ja
Application granted granted Critical
Publication of JP7665339B2 publication Critical patent/JP7665339B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020572773A 2018-07-10 2019-07-10 既存の相互作用を最小化する改変結合分子 Active JP7665339B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025064335A JP2025100662A (ja) 2018-07-10 2025-04-09 既存の相互作用を最小化する改変結合分子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862695988P 2018-07-10 2018-07-10
US62/695,988 2018-07-10
PCT/US2019/041203 WO2020014358A1 (en) 2018-07-10 2019-07-10 Modifying binding molecules to minimize pre-existing interactions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025064335A Division JP2025100662A (ja) 2018-07-10 2025-04-09 既存の相互作用を最小化する改変結合分子

Publications (3)

Publication Number Publication Date
JP2021531245A JP2021531245A (ja) 2021-11-18
JP2021531245A5 JP2021531245A5 (cg-RX-API-DMAC10.html) 2022-07-20
JP7665339B2 true JP7665339B2 (ja) 2025-04-21

Family

ID=67544330

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020572773A Active JP7665339B2 (ja) 2018-07-10 2019-07-10 既存の相互作用を最小化する改変結合分子
JP2025064335A Pending JP2025100662A (ja) 2018-07-10 2025-04-09 既存の相互作用を最小化する改変結合分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025064335A Pending JP2025100662A (ja) 2018-07-10 2025-04-09 既存の相互作用を最小化する改変結合分子

Country Status (16)

Country Link
US (2) US11448651B2 (cg-RX-API-DMAC10.html)
EP (1) EP3820891A1 (cg-RX-API-DMAC10.html)
JP (2) JP7665339B2 (cg-RX-API-DMAC10.html)
KR (1) KR102938177B1 (cg-RX-API-DMAC10.html)
CN (1) CN112543768B (cg-RX-API-DMAC10.html)
AR (1) AR115730A1 (cg-RX-API-DMAC10.html)
AU (1) AU2019302642B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020026784A2 (cg-RX-API-DMAC10.html)
CA (1) CA3104873A1 (cg-RX-API-DMAC10.html)
EA (1) EA202190228A1 (cg-RX-API-DMAC10.html)
IL (2) IL316308B1 (cg-RX-API-DMAC10.html)
MX (2) MX2021000239A (cg-RX-API-DMAC10.html)
MY (1) MY202673A (cg-RX-API-DMAC10.html)
SG (1) SG11202012835RA (cg-RX-API-DMAC10.html)
TW (2) TWI838388B (cg-RX-API-DMAC10.html)
WO (1) WO2020014358A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021000239A (es) 2018-07-10 2021-03-25 Regeneron Pharma Modificacion de moleculas de union para minimizar interacciones preexistentes.
WO2025260062A2 (en) * 2024-06-13 2025-12-18 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting interleukin-4 receptor subunit alpha (il-4ra)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012507294A (ja) 2008-10-29 2012-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−４受容体に対する高親和性ヒト抗体
JP2017532570A (ja) 2014-11-05 2017-11-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ エフェクター機能抑制型ヒトまたはヒト化薬物抗体に対する抗薬物抗体の決定方法
JP2017535547A (ja) 2014-11-14 2017-11-30 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
US20180092975A1 (en) 2016-09-19 2018-04-05 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2004245038A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-CD3 antibody
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP2006380A4 (en) 2006-03-23 2010-08-11 Kyowa Hakko Kirin Co Ltd AGONIST ANTIBODY AGAINST THE HUMAN THROMBOPOIETINE RECEPTOR
WO2009091240A1 (en) 2008-01-15 2009-07-23 Stichting Sanquin Bloedvoorziening Method and kits for detecting antibodies against therapeutic antibodies
NZ592611A (en) * 2008-10-10 2013-01-25 Emergent Product Dev Seattle A single chain fusion protein that binds to tcr complex and does not induce or induces a minimally detectable cytokine release
CA2741114A1 (en) 2008-10-24 2010-04-29 Cornelis Lammert Verweij Biomarkers for predicting the development of chronic autoimmune diseases
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
WO2010122148A1 (en) * 2009-04-24 2010-10-28 Boehringer Ingelheim International Gmbh An improved antibody domain and antibody fragments and antibodies based thereon
TWI507525B (zh) * 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
WO2011074965A1 (en) 2009-12-17 2011-06-23 Stichting Sanquin Bloedvoorziening Methods and means for counteracting an activity of an fc domain
JP2014518632A (ja) 2011-06-01 2014-08-07 モアハウス スクール オブ メディスン ケモカイン−免疫グロブリン融合ポリペプチド、組成物、その作製および使用の方法
MY167125A (en) 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
SG11201506451UA (en) 2013-03-06 2015-09-29 Merrimack Pharmaceuticals Inc Anti-c-met tandem fc bispecific antibodies
TWI755763B (zh) * 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
WO2015187596A2 (en) 2014-06-02 2015-12-10 Regeneron Pharmaceuticals, Inc. Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
CN106999587B (zh) 2014-10-02 2023-09-29 希望之城公司 多价中间表位，中间表位结合抗体及其用途
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
EP4015533A1 (en) * 2015-10-29 2022-06-22 F. Hoffmann-La Roche AG Anti-variant fc-region antibodies and methods of use
WO2017075259A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody formulations
TW201829463A (zh) * 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
PT3515465T (pt) * 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
EP3713966A1 (en) 2017-11-22 2020-09-30 Vacara AB Antibodies to citrullinated proteins
MX2021000239A (es) 2018-07-10 2021-03-25 Regeneron Pharma Modificacion de moleculas de union para minimizar interacciones preexistentes.
US20220244252A1 (en) 2019-06-07 2022-08-04 Sanquin Innovatie B.V. Methods and compounds for typing rheumatoid factors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012507294A (ja) 2008-10-29 2012-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−４受容体に対する高親和性ヒト抗体
JP2017532570A (ja) 2014-11-05 2017-11-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ エフェクター機能抑制型ヒトまたはヒト化薬物抗体に対する抗薬物抗体の決定方法
JP2017535547A (ja) 2014-11-14 2017-11-30 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
US20180092975A1 (en) 2016-09-19 2018-04-05 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Immunology Research，2016年，Article ID 2618575
Journal of Immunology Research，2016年，Article ID 5069678

Also Published As

Publication number Publication date
MY202673A (en) 2024-05-14
IL316308A (en) 2024-12-01
EP3820891A1 (en) 2021-05-19
US12523659B2 (en) 2026-01-13
KR102938177B1 (ko) 2026-03-11
KR20210030378A (ko) 2021-03-17
AR115730A1 (es) 2021-02-17
US20230266333A1 (en) 2023-08-24
US20200018754A1 (en) 2020-01-16
US11448651B2 (en) 2022-09-20
TWI838388B (zh) 2024-04-11
WO2020014358A1 (en) 2020-01-16
MX2021000239A (es) 2021-03-25
AU2019302642B2 (en) 2025-10-30
SG11202012835RA (en) 2021-01-28
CN112543768B (zh) 2024-05-03
CA3104873A1 (en) 2020-01-16
AU2019302642A1 (en) 2021-02-25
BR112020026784A2 (pt) 2021-03-30
IL316308B1 (en) 2026-07-01
JP2021531245A (ja) 2021-11-18
EA202190228A1 (ru) 2021-04-14
CN112543768A (zh) 2021-03-23
IL279803A (en) 2021-03-01
TW202428612A (zh) 2024-07-16
TW202021984A (zh) 2020-06-16
MX2025013509A (es) 2025-12-01
JP2025100662A (ja) 2025-07-03

Similar Documents

Publication Publication Date Title
JP7442581B2 (ja) ヒトｉｌ－４受容体に対する高親和性ヒト抗体
US8613927B2 (en) High affinity human antibodies to human nerve growth factor
CN102574923B (zh) 针对人蛋白酶激活受体-2的高亲和力人抗体
JP6622703B2 (ja) アンタゴニストの、抗イヌｐｄ−１抗体
JP2025100662A (ja) 既存の相互作用を最小化する改変結合分子
EA047574B1 (ru) Модификация связывающих молекул для минимизации уже существующих взаимодействий
EA045437B1 (ru) Антитела человека к bet v 1 и способы их применения
EA040089B1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
HK1144379B (en) High affinity human antibodies to human nerve growth factor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220708

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250409

R150 Certificate of patent or registration of utility model

Ref document number: 7665339

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150